Company profile
Baudax Bio, Inc.
OTC: BXRXQ · Healthcare · Biotechnology
#852 of 1,418 Healthcare companies by revenue64th-percentile growth
EA Score
——FH —DQ 17GM —SS 23
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), listing tenure · ↓ Piotroski F, return on assets
Methodology →Revenue TTM
$310.0k
Rev growth YoY (TTM)
-77.2%
Net income (FY)
-$58.8M
Employees
9
as of 2026-08-30
Market cap
$4.4k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.3M$1.3M2022
Net income-$58.8M-$58.8M2022
Operating income-$56.8M-$56.8M2022
Total assets$10.0M$10.0M2022
Liabilities$34.3M$34.3M2022
Equity-$24.2M-$24.2M2022
Revenue trend
FY2020 – FY2022 · USD
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Baudax Bio, Inc.’s revenue?
Baudax Bio, Inc. booked $1.3M in FY2022 revenue, growing 18% year over year — faster than most Healthcare companies we track, at a -4633.2% net margin.
Peers · Healthcare
Bhang Inc.——Certive Solutions Inc.——VistaGen Therapeutics, Inc.46DSeaStar Medical Holding Corporation30DNRx Pharmaceuticals, Inc.24DLongeveron Inc.30DNeighbors
Chester →Key facts
CEOGerri Henwood
SectorHealthcare
IndustryBiotechnology
HeadquartersMalvern, PA
ExchangeOTC: BXRXQ
Employees9
IPO date2019-11-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.